Heidelberg Pharma AG Stock
Heidelberg Pharma AG Stock
The Heidelberg Pharma AG stock is trending slightly upwards today, with an increase of €0.000 (0.340%) compared to yesterday's price.
So far the community has only identified positive things for Heidelberg Pharma AG stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Heidelberg Pharma AG in the next few years
Pros
?
M***** P*******
?
G***** c******* t* c**********
?
B****
Cons
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Heidelberg Pharma AG vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Heidelberg Pharma AG | 0.340% | 0.000% | -5.079% | -26.536% | -18.750% | -59.041% | -4.777% |
| Nanorepro AG | -1.080% | 6.725% | 5.187% | -19.248% | -11.408% | -81.750% | 53.361% |
| Vivoryon Therapeutics N.V. | -5.110% | 69.379% | 46.211% | -94.158% | -90.162% | -94.619% | -96.313% |
| Jaguar Health Inc. | 3.690% | 13.936% | 105.644% | 114.322% | 10.993% | -99.945% | - |
Comments
systinvest bought the security Heidelberg Pharma AG in his wikifolio Aktienwertselektion mit System.
Show more
News
EQS-News: Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2024
EQS-News: Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2024
EQS-News: Heidelberg Pharma to host R&D Webinar following novel data presented at AACR
EQS-News: Heidelberg Pharma to host R&D Webinar following novel data presented at AACR
EQS-News: Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101
EQS-News: Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101